In this issue

Issue 107 • June 2021

The arrival of the Covid-19 pandemic threw a wrench into the everyday workings of the pharma supply chain. Seemingly overnight, even the most minor of weaknesses in the system became glaringly obvious, and in some cases threatened the global supply of pharmaceutical supplies.

Although the pharma industry has been largely successful in putting out small fires as and when they arise, calls for a serious reimagining of how supply chains function only heightened as it became clear that Covid-19 wasn’t going away any time soon.

But what could a post-pandemic pharma supply chain look like? In this issue, we take a look at some of the key lessons we learn over the past year and how industry can adapt and innovate in order to prevent a similar situation from arising in the future.

Also, we go behind the scenes of the regulation process to find out exactly what it takes to get a new drug brand name approved, examine the potential of an oral Covid-19 vaccine and learn how drug manufacturers are working to improve access to rare disease treatments in India.

All this and more in this latest issue of Pharma Technology Focus.

Eloise Mclennan, editor

Go to article: Home | Relinking the pharma supply chainGo to article: In this issueGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: Datwyler Company Insight Go to article: DatwylerGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: ILC Dover Go to article: ButterworthGo to article: CommentGo to article: New Chinese Breakthrough Therapy designation attracts foreign companiesGo to article: Endometrial cancer patients expected to benefit from novel advancementsGo to article: Regulatory and strategic complications of marketing an oncology drug in AsiaGo to article: The biopharma revolution: navigating complexityGo to article: TRiBECA KnowledgeGo to article: PerkinElmerGo to article: In DepthGo to article: What’s in a drug name?Go to article: Improving care for rare diseases in IndiaGo to article: Focus on the patient, not the pillGo to article: Academic-industry collaborationGo to article: Rewriting the pharma supply chain for a post-pandemic world Go to article: Developing an oral Covid-19 vaccineGo to article: The Solubility Company - Company Insight Go to article: The Solubility companyGo to article: In DataGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue